Negative symptoms, anxiety, and depression as mechanisms of change of a 12-month trial of assertive community treatment as part of integrated care in patients with first- and multi-episode schizophrenia spectrum disorders (ACCESS I trial)

European Archives of Psychiatry and Clinical Neuroscience

Volumn 268, Issue 6, 2018, Pages 593-602

  Schmidt, Stefanie J ^a,b   Lange, Matthias ^c   Schöttle, Daniel ^c   Karow, Anne ^c   Schimmelmann, Benno G ^a,c   Lambert, Martin ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Amotivation; Functioning; Mediation; Negative symptoms; Psychosis; Quality of life

Indexed keywords

QUETIAPINE;

ADULT; ANXIETY DISORDER; ARTICLE; ASSERTIVE TRAINING; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DELUSIONAL DISORDER; DEPRESSION; FEMALE; FUNCTIONAL STATUS; GENERAL CONDITION IMPROVEMENT; GLOBAL ASSESSMENT OF FUNCTIONING; GROUP THERAPY; HUMAN; INTEGRATED HEALTH CARE SYSTEM; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MULTICENTER STUDY; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGICAL WELLBEING ASSESSMENT; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIA SPECTRUM DISORDER; SCHIZOPHRENIFORM DISORDER; SOCIAL AMOTIVATION; SOCIAL BEHAVIOR; STANDARD; TREATMENT RESPONSE; ANXIETY; MENTAL HEALTH SERVICE; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROCEDURES; YOUNG ADULT;

ADULT; ANXIETY; COMMUNITY MENTAL HEALTH SERVICES; DELIVERY OF HEALTH CARE, INTEGRATED; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOTIC DISORDERS; QUALITY OF LIFE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 85019604376     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-017-0810-1     Document Type: Article

References (59)

1. Simonsen C, Sundet K, Vaskinn A, Ueland T, Romm KL, Hellvin T, Andreassen OA (2010) Psychosocial function in schizophrenia and bipolar disorder: relationship to neurocognition and clinical symptoms. J Int Neuropsychol Soc 16(5):771–783
2. Bechdolf A, Pukrop R, Köhn D, Tschinkel S, Veith V, Schultze-Lutter F, Klosterkötter J (2005) Subjective quality of life in subjects at risk for a first episode of psychosis: a comparison with first episode schizophrenia patients and healthy controls. Schizophr Res 79(1):137–143
3. Chugh PK, Rehan HS, Unni KE, Sah RK (2013) Predictive value of symptoms for quality of life in first-episode schizophrenia. Nord J Psychiatry 67(3):153–158
4. Meesters PD, Comijs HC, de Haan L, Smit JH, Eikelenboom P, Beekman ATF, Stek ML (2013) Subjective quality of life and its determinants in a catchment area based population of elderly schizophrenia patients. Schizophr Res 147(2–3):275–280. doi:10.1016/j.schres.2013.04.030
5. Álvarez-Jiménez M, Gleeson JF, Henry LP, Harrigan SM, Harris MG, Killackey E, Bendall S, Amminger GP, Yung AR, Herrman H, Jackson HJ, McGorry PD (2012) Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years. Psychol Med 42(3):595–606
6. Álvarez-Jimenez M, Gleeson JF, Henry LP, Harrigan SM, Harris MG, Amminger GP, Killackey E, Yung AR, Herrman H, Jackson HJ, McGorry PD (2011) Prediction of a single psychotic episode: a 7.5-year, prospective study in first-episode psychosis. Schizophr Res 125(2–3):236–246
7. Burns T (2010) The rise and fall of assertive community treatment? Int Rev Psychiatry 22(2):130–137
8. Armijo J, Méndez E, Morales R, Schilling S, Castro A, Alvarado R, Rojas G (2013) Efficacy of community treatments for schizophrenia and other psychotic disorders: a literature review. Front Psychiatry 4:116
9. Kerkemeyer L, Mostardt S, Biermann J, Wasem J, Neumann A, Walendzik A, Jahn R, Bartels C, Falkai P, Brannath W, Breunig-Lyriti V, Mester B, Timm J, Wobrock T (2015) Evaluation of an integrated care program for schizophrenia: concept and study design. Eur Arch Psychiatry Clin Neurosci 265(2):155–162
10. Karow A, Reimer J, König HH, Heider D, Bock T, Huber C, Lambert M (2012) Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry 73(3):402–408
11. Lambert M, Bock T, Schöttle D, Golks D, Meister K, Rietschel L, Schimmelmann BG (2010) Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry 71(10):1313–1323
12. Frazier PA, Trix AP, Barron KE (2004) Testing moderator and mediator effects in counseling psychology research. J Couns Psychol 51(1):115–134
13. Baron RM, Kenny DA (1986) The moderator—mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51(6):1173–1182
14. Bowie CR, Depp C, McGrath JA, Wolyniec P, Mausbach BT, Thornquist MG, Pulver AE (2010) Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. Am J Psychiatry 167(9):1116–1124
15. Chudleigh C, Naismith SL, Blaszczynski A, Hermens DF, Hodge M, Hickie IB (2011) How does social functioning in the early stages of psychosis relate to depression and social anxiety? Early Interv Psychiatry 5(3):224–232
16. Hayhurst KP, Drake RJ, Massie JA, Dunn G, Barnes TR, Jones PB, Lewis SW (2014) Improved quality of life over one year is associated with improved adherence in patients with schizophrenia. Eur Psychiatry 29(3):191–196
17. Margariti M, Ploumpidis D, Economou M, Christodoulou GN, Papadimitriou GN (2015) Quality of life in schizophrenia spectrum disorders: associations with insight and psychopathology. Psychiatry Res 225(3):695–701
18. Liemburg E, Castelein S, Stewart R, van der Gaag M, Aleman A, Knegtering H (2013) Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. J Psychiatry Res 47(6):718–725
19. Galderisi S, Merlotti E, Mucci A (2015) Neurobiological background of negative symptoms. Eur Arch Psychiatry Clin Neurosci 265(7):543–558
20. Boyette LL, Korver-Nieberg N, Meijer C, de Haan L (2014) Quality of life in patients with psychotic disorders: impact of symptoms, personality, and attachment. J Nerv Ment Dis 202(1):64–69
21. Gade K, Malzahn D, Anderson-Schmidt H, Strohmaier J, Meier S, Frank J, Schulze TG (2015) Functional outcome in major psychiatric disorders and associated clinical and psychosocial variables: a potential cross-diagnostic phenotype for further genetic investigations? World J Biol Psychiatry 16(4):237–248
22. Blanchard JJ, Cohen AS (2006) The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull 32(2):238–245
23. Chiappelli J, Nugent KL, Thangavelu K, Searcy K, Hong LE (2013) Assessment of trait and state aspects of depression in schizophrenia. Schizophr Bull 40(1):132–142
24. Kirkpatrick B, Galderisi S (2008) Deficit schizophrenia: an update. World Psychiatry 7(3):143–147
25. An der Heiden W, Leber A, Häfner H (2016) Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia. Eur Arch Psychiatry Clin Neurosci 266(5):387–396
26. Schmidt SJ, Schimmelmann BG (2015) Mechanisms of change in psychotherapy for children and adolescents: current state, clinical implications, and methodological and conceptual recommendations for mediation analysis. Eur Child Adolesc Psychiatry 24(3):249–253
27. Ventura J, Liberman RP, Green MF, Shaner A, Mintz J (1998) Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Res 79(2):163–173
28. McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ (1996) EPPIC: an evolving system of early detection and optimal management. Schizophr Bull 22(2):305–326
29. Ritsner MS, Kurs R, Gibel A (2005) Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual Life Res 14(7):1693–1703
30. Kay SR, Falzbein A, Opfer LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276
31. Sass H, Wittchen HU, Zaudig M, Houben I (2003) Diagnostische kriterien des diagnostischen und statistischen manuals psychischer störungen. DSM-IV-TR. Hogrefe, Göttingen
32. Hayes AF (2013) Introduction to mediation, moderation, and conditional process analysis: a regression-based approach. The Guilford Press, New York
33. Tucker LR, Lewis C (1973) A reliability coefficient for maximum likelihood factor analysis. Psychometrika 38(1):1–10
34. Bentler PM (1990) Comparative fit indexes in structural models. Psychol Bull 107(2):238–246
35. Steiger JH (1990) Structural model evaluation and modification: an interval estimation approach. Multivariate Behav Res 25(2):173–180
36. Bentler PM (1992) On the fit of models to covariances and methodology to the Bulletin. Psychol Bull 112(3):400–404
37. Preacher KJ, Hayes A (2004) SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav Res Methods Instrum Comput 36(4):717–731
38. Brown TA (2006) Confirmatory factor analysis for applied research. The Guilford Press, New York
39. Spratt M, Carpenter J, Sterne JA, Carlin JB, Heron J, Henderson J, Tilling K (2010) Strategies for multiple imputation in longitudinal studies. Am J Epidemiol 172:478–487
40. Green MF, Hellemann G, Horan WP, Lee J, Wynn JK (2012) From perception to functional outcome in schizophrenia: modelling the role of ability and motivation. Arch Gen Psychiatry 69(12):1216–1224
41. Kring AM, Gur RE, Blanchard JJ, Horan WP, Reise SP (2013) The clinical assessment interview for negative symptoms (CAINS): final development and validation. Am J Psychiatry 170(2):165–172
42. Quinlan T, Roesch S, Granholm E (2014) The role of dysfunctional attitudes in models of negative symptoms and functioning in schizophrenia. Schizophr Res 157(1–3):182–189
43. Chang WC, Kwong VW, Hui CL, Chan SK, Lee EH, Chen EY (2016) Relationship of amotivation to neurocognition, self-efficacy and functioning in first-episode psychosis: a structural equation modeling approach. Psychol Med 47(4):755–765
44. Strauss GP, Gold JM (2012) A new perspective on anhedonia in schizophrenia. Am J Psychiatry 169(4):364–373
45. Engel M, Fritzsche A, Lincoln TM (2016) Anticipation and experience of emotions in patients with schizophrenia and negative symptoms. An experimental study in a social context. Schizophr Res 170(1):191–197
46. Barch DM, Treadway MT, Schoen N (2014) Effort, anhedonia, and function in schizophrenia: reduced effort allocation predicts amotivation and functional impairment. J Abnorm Psychol 123(2):387–397
47. Strauss GP, Whearty KM, Morra LF, Sullivan SK, Ossenfort KL, Frost KH (2016) Avolition in schizophrenia is associated with reduced willingness to expend effort for reward on a progressive ratio task. Schizophr Res 170(1):198–204
48. Buck B, Lysaker PH (2013) Consummatory and anticipatory anhedonia in schizophrenia: stability, and associations with emotional distress and social function over six months. Psychiatry Res 205(1–2):30–35
49. Grant PM, Beck AT (2009) Defeatist beliefs as a mediator of cognitive impairment, negative symptoms, and functioning in schizophrenia. Schizophr Bull 35(4):798–806
50. Wolf DH, Satterthwaite TD, Kantrowitz JJ, Katchmar N, Vandekar L, Elliott MA, Ruparel K (2014) Amotivation in schizophrenia: integrated assessment with behavioural, clinical, and imaging measures. Schizophr Bull 40(6):1328–1337
51. Del-Monte J, Raffard S, Salesse RN, Marin L, Schmidt RC, Varlet M, Bardy BG, Philippe Boulenger J, Christine Gély-Nargeot M, Capdevielle D (2013) Nonverbal expressive behaviour in schizophrenia and social phobia. Psychiatry Res 210(1):29–35
52. Krauss RM, Chen Y, Chawla P (1996) Nonverbal behavior and nonverbal communication: what do conversational hand gestures tell us? Adv Exp Soc Psychol 28:389–450
53. Bell M, Tsang HW, Greig TC, Bryson GJ (2009) Neurocognition, social cognition, perceived social discomfort, and vocational outcomes in schizophrenia. Schizophr Bull 35(4):738–747
54. Brekke JS, Hoe M, Long J, Green MF (2007) How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia. Schizophr Bull 33(5):1247–1256
55. Kaiser SL, Snyder JA, Corcoran R, Drake RJ (2006) The relationships among insight, social support, and depression in psychosis. J Nerv Ment Dis 194(12):905–908
56. Alessandrini M, Lançon C, Fond G, Faget-Agius C, Richieri R, Faugere M, Metairie E, Boucekine M, Llorca PM, Auquier P, Boyer L (2016) A structural equation modelling approach to explore the determinants of quality of life in schizophrenia. Schizophr Res 171(1–3):27–34
57. Urben S, Baier V, Mantzouranis G, Pigois E, Graap C, Dutoit F, Cherix-Parchet M, Henz C, Faucherand A, Senent E, Holzer L (2015) Predictors and moderators of clinical outcomes in adolescents with severe mental disorders after an assertive community treatment. Child Psychiatry Hum Dev 46(6):997–1005
58. Schmidt SJ, Mueller DR, Roder V (2011) Social cognition as a mediator variable between neurocognition and functional outcome in schizophrenia: empirical review and new results by structural equation modelling. Schizophr Bull 37(Suppl. 2):41–54
59. Hayduk LA, Littvay L (2012) Should researchers use single indicators, best indicators, or multiple indicators in structural equation models? BMC Med Res Methodol 12:159